Insulet (NASDAQ:PODD) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft

Analysts at Deutsche Bank Aktiengesellschaft started coverage on shares of Insulet (NASDAQ:PODD) in a report released on Tuesday. The firm set a “buy” rating and a $190.00 price target on the medical instruments supplier’s stock. Deutsche Bank Aktiengesellschaft’s target price would indicate a potential upside of 36.72% from the company’s previous close.

A number of other brokerages have also issued reports on PODD. Sanford C. Bernstein cut their target price on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Citigroup dropped their price objective on Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Rothschild & Co Redburn reiterated a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a report on Friday, April 24th. JPMorgan Chase & Co. cut their price objective on Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. Finally, Wells Fargo & Company reduced their price objective on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Twenty-two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $238.67.

Insulet Stock Down 4.7%

Shares of PODD opened at $138.97 on Tuesday. The company’s 50-day moving average price is $162.97 and its 200 day moving average price is $224.47. Insulet has a 12-month low of $138.79 and a 12-month high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The firm has a market cap of $9.63 billion, a P/E ratio of 32.32, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the firm posted $1.02 earnings per share. Insulet’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, sell-side analysts forecast that Insulet will post 6.46 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Insulet

Hedge funds have recently modified their holdings of the business. Empowered Funds LLC grew its holdings in shares of Insulet by 38.1% during the first quarter. Empowered Funds LLC now owns 2,880 shares of the medical instruments supplier’s stock worth $604,000 after buying an additional 795 shares during the last quarter. Avidity Partners Management LP acquired a new position in shares of Insulet in the first quarter valued at approximately $2,098,000. Glenmede Trust Co. NA raised its stake in shares of Insulet by 6.5% during the first quarter. Glenmede Trust Co. NA now owns 2,717 shares of the medical instruments supplier’s stock worth $570,000 after purchasing an additional 166 shares during the last quarter. Essential Partners LLC lifted its holdings in shares of Insulet by 9,980.0% during the first quarter. Essential Partners LLC now owns 504 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 499 shares during the period. Finally, Western Wealth Management LLC purchased a new position in Insulet in the 1st quarter valued at $80,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.